SAN DIEGO, March 13, 2025--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback